AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 5 - (NewsRx.com & NewsRx.net) -- New research suggests that the combination of Navelbine (vinorelbine tartrate) Injection, a first-line chemotherapy treatment for advanced non-small cell lung cancer, and the monoclonal antibody therapy Heceptin (trastuzumab) is a promising and generally well tolerated treatment for HER2 positive metastatic breast cancer and warrants further study
Navelbine is not currently indicated for use in women with metastatic breast cancer.
The multicenter open-label trial enrolled 40 women with metastatic disease (spread to sites in the body beyond the breast) whose tumors over-expressed the HER2Neu oncogene, a growth-promoting protein that has been closely linked to a poor prognosis in breast cancer, and were therefore candidates for Herceptin therapy. The study was designed to determine if the addition of Navelbine would increase the expected response rate to Herceptin therapy without significantly increasing serious side effects.
Mohammad Jahanzeb, MD, chief, division of hematology/oncology at the University of Tennessee College of Medicine, led the group of investigators from seven cancer centers across the United States.
Weekly intravenous doses of Herceptin and Navelbine were administered over 4-week courses. Thirty-seven patients were evaluated for a response after receiving at least two courses. ...
Source: HighBeam Research, Phase II trial of Navelbine plus Herceptin for HER2 looks promising.